DT
Therapeutic Areas
AbCellera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ABCB-101 (AbbVie Partnered) | Oncology (Undisclosed) | Pre-clinical |
| ABCB-102 (Novartis Partnered) | Immunology (Undisclosed) | Pre-clinical |
| ABCB-103 (Gilead Partnered) | Oncology (Undisclosed) | Pre-clinical |
| LY-CoV555 (Bamlanivimab) | COVID-19 | Emergency Use Authorization (Past) |
| Internal Program 1 | Undisclosed Oncology Target | Lead Optimization |
| Internal Program 2 | Undisclosed Immunology Target | Lead Optimization |
Leadership Team at AbCellera
DC
Dr. Carl Hansen
Co-founder & Chief Executive Officer
DV
Dr. Véronique Lecault
Co-founder & Chief Operating Officer
MM
Murray McCutcheon
Co-founder & Senior Vice President, Corporate Development
AB
Andrew Booth
Chief Financial Officer
DE
Dr. Ester Falconer
Senior Vice President, Discovery & Technology
DJ
Dr. Jane N.
Senior Vice President, Therapeutics
PG
Patrick Grady
Chair of the Board of Directors
DS
Dr. Sarah Larson
Board Member
DM
Dr. Michael Hayden
Board Member